Clinical trial · no report yet · Phase 2
ELIOS
A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
- NCT03239340 ↗
- Completed
- AstraZeneca
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 7 | |
| X threads | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
- Phase
- Phase 2
- Status
- Completed
- Conditions
- EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- Osimertinib
- Arms
- Osimertinib · Experimental
- Enrollment
- 154
- Primary outcomes
- Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression
- Sponsor
- AstraZeneca with Parexel
- Start
- May 30, 2018
- Primary completion
- Sep 19, 2023
- Results posted
- Yes
- Registry record
- NCT03239340 · updated Oct 21, 2024